Impaired integration of endothelial progenitor cells in capillaries of diabetic wounds is reversible with vascular endothelial growth factor infusion.
To understand impaired angiogenesis in diabetic wounds, polyvinyl tubes were implanted subcutaneously in rats to form a granulation tissue for 2 weeks and the granulation tissue was studied after inducing diabetes with streptozotocin. By 1 week of diabetes, the granulation tissue was bloody and thinner than controls, its medial layer was depleted of microvessels, and the surviving vessels appeared dehisced. Vascular endothelial growth factor (VEGF) in the diabetic granulation tissue was reduced by 50% compared with control granulation tissue. After 3 days of diabetes, the diabetic tissue showed a greater degree of apoptosis in the microvessels. Chemotactic factors [stromal cell-derived factor-1alpha and chemokine receptor-4 (CXCR-4)], responsible for attracting bone marrow cells, showed equal intensity in control and diabetic tissues. As expected, progenitor endothelial CD-34 cells were observed in abundance in both the control and the diabetic granulation tissues. However, although the CD-34-positive cells appeared mostly to be integrated in the blood vessels of the control tissue, fewer such cells were present in the blood vessels of the diabetic tissues, suggesting that CD-34 failed to integrate into new blood vessels. Infusion of VEGF in the granulation tissue of diabetic rats for 1 week resulted in complete prevention of the microvascular defect compared with the contralateral granulation tissue that showed the typical diabetic changes. It was concluded that diabetes causes reduction of VEGF in the wound, resulting in loss of blood vessels by apoptosis and possible failure of CD-34 cells to integrate into the vessel structure.
Singh
Ashok K
AK
Division of Nephrology, Cook County Hospital, Chicago, IL 60612, USA. singhashok@comcast.net
Gudehithlu
Krishnamurthy P
KP
Patri
Shreya
S
Litbarg
Natalia O
NO
Sethupathi
Perianna
P
Arruda
Jose A L
JA
Dunea
George
G
D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism*; D001808:Blood Vessels / Q000473:pathology; D001826:Body Fluids / Q000378:metabolism; D002196:Capillaries / Q000187:drug effects / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D042783:Endothelial Cells / Q000378:metabolism*; D006097:Granulation Tissue / Q000098:blood supply / Q000473:pathology / Q000503:physiopathology; D006099:Granuloma / Q000378:metabolism; D008297:Male; D008833:Microcirculation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013234:Stem Cells / Q000378:metabolism*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*
D018952:Antigens, CD34; D042461:Vascular Endothelial Growth Factor A